The Just MS (Multiple Sclerosis) Show

Justin Loizos

A podcast about multiple sclerosis hosted by Justin Loizos. Each episode will explore the world of MS. This will either be done through interviews with MS stakeholders or with Justin providing information about the illness. Thank you for listening. 

  1. 2d ago

    New Clues to MS Damage, GLP-1 Drug Research & Progression Beyond Relapses | Just MS News

    Send us Fan Mail How can we better understand MS damage—and recognise progression when relapses aren’t happening? This week on Just MS News, Justin Loizos explores new research into MS damage, GLP-1 drugs and progression beyond relapses, alongside more research and community headlines. TOP THREE STORIES New clues to MS damage Research examining the lining of the brain’s fluid-filled spaces and its possible role in MS. Nature Neuroscience: https://www.nature.com/articles/s41593-026-02461-3GLP-1 drugs and MS What researchers are investigating, what the available evidence can tell us, and which questions remain unanswered. Bioengineer.org: https://bioengineer.org/glp-1-drugs-like-ozempic-face-a-new-test-multiple-sclerosis/Progression beyond relapses Tracking walking, hand function, thinking speed and everyday experiences to better understand changes in MS. Vall d’Hebron / Cemcat: https://www.vallhebron.com/en/news/news/severity-questionnaire-and-tests-patients-can-perform-themselves-enable-detection-multiple-sclerosis-progression-independent-relapsesMORE MS NEWS — THIS WEEK’S SHORTLIST • NAC and brain imaging research MedPage Today: https://www.medpagetoday.com/meetingcoverage/asfnr/123392 • Disparities in starting MS treatment National MS Society: https://www.nationalmssociety.org/news-and-magazine/news/dmt-initiation-disparities • Vagus nerve stimulation and hand rehabilitation NR Times: https://nrtimes.co.uk/vagus-nerve-stimulation-may-improve-ms-hand-rehab-therapy25/ • B-cell therapy and antiviral immunity Bioengineer.org: https://bioengineer.org/b-cell-depletion-therapy-reshapes-antiviral-immunity-in-multiple-sclerosis-study-finds/ • Digital tracking of daily MS symptoms Bioengineer.org: https://bioengineer.org/digital-symptom-tracking-reveals-how-multiple-sclerosis-patients-really-fare-day-to-day/ • Community: Bike MS New York CBS News New York: https://www.cbsnews.com/newyork/news/nyc-bike-ms-road-closures-october-18-2026/ Which story stood out to you? Share your thoughts or experience in the comments. More MS news and our newsletter: https://www.justmultiplesclerosis.com Subscribe for weekly MS news, research and community stories. Some linked sources may require a subscription or institutional access. Research findings and experimental approaches should not be taken as proof of treatment benefit. For information and discussion, not personal medical advice. #MultipleSclerosis #MSResearch #JustMSNews The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    New Clues to MS Damage, GLP-1 Drug Research & Progression Beyond Relapses | Just MS News
  2. Oct 13

    Ocrevus: 10-Year Results, Myelin Repair Funding & MSToronto2026 | Just MS News

    Send us Fan Mail What can long-term treatment research tell us about living with MS—and what will it take to move myelin repair research forward? This week on Just MS News, Justin Loizos explores three stories connecting treatment, research funding and the MS community. OCREVUS: TEN-YEAR FINDINGS We examine the ten-year OPERA follow-up published in JAMA Neurology, what it suggests about starting ocrelizumab earlier in relapsing MS, and the limitations of interpreting long-term extension data. MYELIN REPAIR: THE FUNDING BEHIND THE RESEARCH Rewind Therapeutics has announced additional financing for its experimental oral GPR17 program. We revisit the mouse findings, explain why funding matters, and distinguish promising preclinical research from evidence that a treatment helps people. This announcement reports no new human treatment results. MSTORONTO2026: RESEARCH AND COMMUNITY The joint ACTRIMS–ECTRIMS meeting comes to Toronto October 21–23. We preview upcoming research, including planned remibrutinib results, and highlight Patient Community Day on October 23, with in-person and online participation. I’m excited about the opportunity and hoping I can attend. Disclosure: I have been taking Ocrevus for about four years and have worked with Roche on its co-creation council. SOURCES AND EVENT INFORMATION JAMA Neurology — Ten-year OPERA follow-up, Hauser and colleagues Rewind Therapeutics — October 6 financing announcement PLOS ONE — GPR17 preclinical study, De Herdt and colleagues Novartis — Upcoming MSToronto2026 presentations MSToronto2026 — Official conference website Patient Community Day — Information and registration What question would you most like MS researchers to answer? Share it in the comments, and subscribe for more Just MS News. Episode covering October 6–12, 2026. #MultipleSclerosis #MSNews #Ocrevus The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    Ocrevus: 10-Year Results, Myelin Repair Funding & MSToronto2026 | Just MS News
  3. Oct 6

    FDA Reviews Fenebrutinib, Remyelination Trial Begins & New MS Inflammation Target | Just MS News

    Send us Fan Mail This week in Just MS News, we cover three important developments across the MS research pipeline. The FDA has begun Priority Review of fenebrutinib for both relapsing MS and primary progressive MS, following three major Phase III trials. We also revisit PRO-1562, a remyelination therapy we’ve followed before, as it moves from preclinical research into its first Phase 1/2a human study. And researchers have identified a new inflammatory pathway involving HPGDS and PGD₂ that may help drive Th17-cell activity in MS. Human blood and cell findings supported the pathway, while blocking it reduced MS-like disease in mice. Also on the shortlist this week: • Continuing CAR-T safety questions in autoimmune trials • The 2026 Rachel Horne Prize recognizing research on women and MS • A&W Canada and MS Canada raising $1.56 million through Burgers to Beat MS As always, the goal is to separate what the research actually shows from what it does not — without hype or information overload. SOURCES & ARTICLES FDA Begins Priority Review of Fenebrutinib for Relapsing and Primary Progressive MS Source: BioPharma Dive https://www.biopharmadive.com/news/roche-fenebrutinib-ms-fda-accept-application-btk/831746/ Primary source: Roche https://www.roche.com/media/releases/med-cor-2026-09-30 PRO-1562 Enters First Phase 1/2a Human Study Focused on Remyelination Source: AllSci https://allsci.com/news/clinical-trials/pro-1562-multiple-sclerosis-trial-progentos/ Targeting the HPGDS-PGD₂ Axis to Treat Th17 Cell-Mediated Autoimmunity in Multiple Sclerosis Source: Signal Transduction and Targeted Therapy / Nature Portfolio https://www.nature.com/articles/s41392-026-02937-5 Autoimmune Researchers Seek Answers After Deaths in CAR-T Cell Trials Source: Medscape https://www.medscape.com/viewarticle/autoimmune-researchers-seek-answers-after-deaths-car-t-cell-2026a10010xi Recognising Excellence in Women’s MS Research — 2026 Rachel Horne Prize Source: MS Trust https://mstrust.org.uk/news/recognising-excellence-womens-ms-research A&W and MS Canada Celebrate $1.56 Million Raised Through Burgers to Beat MS Source: A&W Canada / MS Canada / Newswire https://www.newswire.ca/news-releases/a-amp-w-and-ms-canada-celebrate-outstanding-generosity-from-canadians-with-1-56-million-raised-from-burgers-to-beat-ms--899132706.htmlThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    FDA Reviews Fenebrutinib, Remyelination Trial Begins & New MS Inflammation Target | Just MS News
  4. Sep 22

    Alpha-Lipoic Acid Advances | EBV Before Relapse, Ocrevus & CAR-T - Just MS News

    Send us Fan Mail This week in Just MS News: Alpha-lipoic acid has passed an important interim checkpoint in the phase 3 OCTOPUS trial for progressive MS, while metformin will not continue. This does not yet prove ALA slows disability progression, but it has shown enough potential to keep testing. A new Nature Medicine study also found EBV-related immune changes appearing roughly 30–90 days before confirmed MS relapses. The findings strengthen the link between EBV, B cells and MS activity, but do not prove EBV caused the relapses. European regulators have recommended expanding Ocrevus to people aged 10+ with active relapsing MS. We also cover a newly cleared C-CAR168 CAR-T trial for progressive MS and early Manitoba research into NRG-1 and myelin repair. SOURCES OCTOPUS / Alpha-Lipoic Acid https://www.ucl.ac.uk/news/2026/sep/existing-drug-shows-early-promise-treat-progressive-ms https://ms-octopus.mrcctu.ucl.ac.uk/ EBV Before MS Relapse — Nature Medicine https://www.nature.com/articles/s41591-026-04665-3 Ocrevus / Pediatric MS https://www.roche.com/media/releases/med-cor-2026-09-18 https://www.ema.europa.eu/en/medicines/human/variation/ocrevus C-CAR168 CAR-T / Progressive MS https://www.neurologylive.com/view/fda-clears-c-car168-trial-refractory-progressive-multiple-sclerosis NRG-1 / Manitoba Research https://umtoday.ca/stories/potential-new-ms-treatment-may-restore-brain-function https://www.nature.com/articles/s41467-026-72639-7 Just Multiple Sclerosis https://justmultiplesclerosis.com Just MS News is for education and discussion and is not medical advice. Discuss treatment decisions, supplements or changes to your care with your healthcare team. #MultipleSclerosis #MSNews #ProgressiveMS #MSResearch #Ocrevus #EBV #CART #SPMS #PPMS The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    Alpha-Lipoic Acid Advances | EBV Before Relapse, Ocrevus & CAR-T - Just MS News
  5. Sep 14

    Early MS Treatment, Late-Onset Progression & What Drives MS Fatigue | Just MS News

    Send us Fan Mail This week on Just MS News, we look at new research examining three very different parts of living with multiple sclerosis. Our lead story follows more than 500 newly diagnosed people with MS and compares early treatment strategies. B-cell-depleting therapies were linked with fewer relapses and less MRI activity — but after two years, researchers did not find a significant difference in disability. We also examine new research into late-onset MS. In an Egyptian cohort, people whose MS began later in life experienced fewer relapses but reached confirmed disability progression sooner — highlighting why relapse activity does not always tell the whole story. Then we look at MS fatigue. A study of people with relapsing-remitting MS found fatigue often appeared alongside poor sleep, pain, stress, anxiety, walking difficulties and heat sensitivity. The study shows associations, not cause and effect, but it raises an important practical question: what else may be adding to someone’s fatigue? Plus, we finish with one more quick MS update. Just MS News covers multiple sclerosis research carefully, without hype, with a focus on what the evidence actually means for people living with MS. SOURCES & RESEARCH Early MS treatment choices Uibel P. et al. Therapy Choices and Outcomes in Newly Diagnosed Multiple Sclerosis: The Pan-European MultipleMS Study Neurology Open Access, September 2026 https://doi.org/10.1212/WN9.0000000000000168 Late-onset MS and disability progression Fouad AM, Saad AA, Abd El-Aziz HM, Elelwany DA. Late-Onset Versus Adult-Onset Multiple Sclerosis: A Comparative Analysis of Clinical, Radiological, and Confirmed Disability Progression Multiple Sclerosis and Related Disorders, September 11, 2026 https://doi.org/10.1016/j.msard.2026.107923 MS fatigue and contributing factors Naghilou S. et al. Fatigue and contributing factors in relapsing-remitting multiple sclerosis: a descriptive study based on the comprehensive fatigue assessment battery for multiple sclerosis (CFAB-MS) Neurological Sciences, August 27, 2026 https://doi.org/10.1007/s10072-026-09353-1 NR Times coverage, September 11, 2026: https://nrtimes.co.uk/fatigue-in-relapsing-remitting-ms-linked-to-pain-sleep-stress-study-finds-care26/ This content is for education and discussion and is not a substitute for individual medical advice. Treatment decisions should be discussed with your MS care team. #MultipleSclerosis #MSResearch #MSNews #LivingWithMS The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    Early MS Treatment, Late-Onset Progression & What Drives MS Fatigue | Just MS News
  6. Sep 7

    3 Deaths Halt CAR-T Trials | This Week in Multiple Sclerosis

    Send us Fan Mail This week on Just MS News, we lead with a difficult but important story: Novartis has paused eight CAR-T clinical trials after three patient deaths linked to severe immune reactions. These are not simply numbers in a clinical trial or events affecting a company's share price. They were people who entered research hoping for something better. We look at what happened, what it may mean for CAR-T research in multiple sclerosis, and why patient safety has to remain at the centre of this conversation. I also share some of my own perspective. Early in my MS journey, I was offered the possibility of HSCT and ultimately decided the risks were more than I was personally prepared to accept. Decisions involving experimental or high-risk treatments are deeply personal, and stories like this are a reminder of what patients are sometimes being asked to weigh. A quick personal note: this week's episode is shorter than usual because I've been dealing with some of my own MS-related issues. Rather than miss the week entirely, I focused on our lead story and kept the remaining stories concise. This week's stories and sources 1. Novartis halts eight CAR-T cell therapy trials after deaths Source: EMJ GOLD Read the original article 2. Remibrutinib reports positive Phase 3 results in relapsing MS Source: Novartis Read the Novartis announcement 3. In-vivo CAR-T shows early promise in autoimmune disease, including MS Source: Nature Read the Nature article 4. Targeted MS therapy uses patients' red blood cells to curb autoimmune attacks Source: Medical Xpress Read the article 5. Aging and cellular senescence as possible drivers of MS progression Source: Journal of Neuroscience Read the paper 6. DMTs associated with higher risk of some gynecologic complications Source: NeurologyLive Read the article 7. Real-world infection risk with B-cell-depleting MS therapy Source: NEJM Clinician Read the article 8. Researchers investigate shared biology behind profound fatigue Source: Medical Xpress Read the article 9. Funding boost for an EBV vaccine with possible future MS-prevention relevance Source: National Tribune Read the article 10. Genetic score may help predict lymphopenia risk with dimethyl fumarate Source: NeurologyLive Read the article As always, Just MS News is about following the science without losing sight of the people behind it. Subscribe for weekly multiple sclerosis news, research updates and patient perspective. Sources and story selection are based on the September 1–7 weekly article collection. The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    3 Deaths Halt CAR-T Trials | This Week in Multiple Sclerosis
  7. Sep 1

    Can Walking Data Reveal MS Progression Earlier? + EBV Vaccine Research | Just MS News 25 - 31/08 2026

    Send us Fan Mail This week on Just MS News, we break down some of the most important multiple sclerosis research and developments from August 25–31, 2026. Our top stories: 🚶 Everyday Walking Data & MS Progression Researchers are looking at whether real-world walking measurements could help reveal MS progression earlier. Source: Multiple Sclerosis Journal 🦠 EBV, MS & the Push for a Vaccine The connection between Epstein-Barr virus and multiple sclerosis continues to drive research into whether preventing EBV infection could ultimately help prevent MS. Sources: Technology Networks / ClinicalTrials.gov 🧠 Recovery vs. Compensation in MS Rehabilitation New rehabilitation research explores an important distinction: are people actually recovering neurological function, or learning better ways to compensate for impairment? Source: International Journal of MS Care Also in this week’s MS news: neurogenic bladder, treatment-access updates, MS nursing, BTK research in the central nervous system, family screening, distinguishing MS from MOGAD, and stories from people living and working in the MS community. Just MS News cuts through the noise to focus on MS research, treatment, rehabilitation and the developments that matter to people living with multiple sclerosis. 👍 Like the video if you found it useful.  💬 Tell me which story you want me to explore further.  🔔 Subscribe for weekly MS news, interviews and deeper discussions. For information and more Just MS content: justmultiplesclerosis.com This content is for educational and informational purposes and is not medical advice. Always discuss treatment or healthcare decisions with a qualified medical professional. #MultipleSclerosis #MSResearch #MSNews #MultipleSclerosisResearch #MSAwareness #JustMSNews #LivingWithMS The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    Can Walking Data Reveal MS Progression Earlier? + EBV Vaccine Research | Just MS News 25 - 31/08 2026
  8. Aug 24

    Could Your Eyes Reveal MS Progression? + The Race to Repair Myelin | Just MS News 18 - 24-08-2026

    Send us Fan Mail This week on Just MS News, we’re focusing on two important areas of multiple sclerosis research: understanding progression and repairing damage. 👁️ Could your eyes reveal clues about MS progression? Researchers are investigating whether measurements of retinal layers using OCT — optical coherence tomography — could help identify people at greater risk of future cognitive progression. The study specifically looked at cognitive PIRA — progression independent of relapse activity — and raises an intriguing possibility: could a relatively simple eye scan eventually provide another window into what is happening elsewhere in the nervous system? 🧠 The race to repair myelin Researchers in Germany are developing a transdermal patch designed to deliver low, steady doses of theophylline as a potential approach to promoting remyelination. The patch has NOT been shown to repair myelin in people with MS. It remains experimental and is moving toward early human testing. But the bigger story is how many different approaches researchers are now taking toward remyelination. We look at the new patch alongside some of the other myelin-repair research we’ve been following. This week’s sources: 🔶 Retinal layers and cognitive progression in MS https://visualize.jove.com/42562954-Retinal-layers-prognosticate-cognitive-progression-independent-of-relapse-activity-in-multiple-sclerosis 🔶 A Transdermal Patch to Promote Remyelination in Multiple Sclerosis Patients — Johannes Gutenberg University Mainz https://cnb-idn.biologie.uni-mainz.de/a-transdermal-patch-to-promote-remyelination-in-multiple-sclerosis-patients/ For the complete weekly MS news digest — including stories that don’t make the video — visit: https://justmultiplesclerosis.com Understand the progression. And, hopefully one day, repair the damage. Just MS News provides news and information for the MS community and is not medical advice. Always discuss medical decisions with your healthcare team The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

    Could Your Eyes Reveal MS Progression? + The Race to Repair Myelin | Just MS News 18 - 24-08-2026

About

A podcast about multiple sclerosis hosted by Justin Loizos. Each episode will explore the world of MS. This will either be done through interviews with MS stakeholders or with Justin providing information about the illness. Thank you for listening. 

You Might Also Like